No Data
beijing sl pharmaceutical (002038.SZ) obtained the registration certificate for desloratadine tablets pharmaceutical.
beijing sl pharmaceutical (002038.SZ) announced that the company recently received the State Food and Drug Administration (referred to as the "State Food...
Beijing SL Pharmaceutical (002038.SZ): Key products that have entered the national centralized procurement include temozolomide, lenalidomide, and ornidazole.
Gelonghui, November 13th - Beijing SL Pharmaceutical (002038.SZ) stated during a specific research session on November 12, 2024, that among the company's key products, the pharmaceuticals included in the national centralized procurement are temozolomide, lenalidomide, and metronidazole. The pharmaceuticals included in inter-provincial alliances and local centralized procurement are recombinant human granulocyte stimulating factor injection, thymopentin, interleukin-2, interleukin-11, cyclosporine, and other pharmaceuticals. Currently, most of the company's main varieties that may be included in centralized procurement have been included. Subsequently, most of the products included in centralized procurement are those with relatively small market share and newly approved products, and the company will adopt a strategy of exchanging price for market access.
Beijing sl pharmaceutical (002038.SZ): It is expected that next year, the company will not be adversely affected by significant fluctuations in stock prices.
GeLongHui November 13th | beijing sl pharmaceutical (002038.SZ) stated during a specific research interview on November 12, 2024, that the situation is expected to improve next year. In the future, the company will participate in the national centralized procurement of most new varieties that have been listed in the past one or two years, and the significant price reductions will not bring negative impacts, possibly becoming a new source of incremental revenue. The company's financial assets are currently at relatively low levels, and it is expected that substantial fluctuations in stock prices next year will not adversely affect the company.
Shuanglu Pharmaceutical: Report for the third quarter of 2024
Beijing SL Pharmaceutical (002038.SZ): has already established an mRNA platform
Ge Longhui October 21st | Beijing SL Pharmaceutical (002038.SZ) stated on the investor interaction platform that the company has established an mRNA platform, currently layout in the infectious disease treatment vaccine field and the tumor vaccine field, and the research of related products is still in the preclinical stage.
Beijing SL Pharmaceutical (002038.SZ): Executive Liang Shujie completed the shareholding of 0.5 million shares.
On October 16, Gelonhui reported that Beijing SL Pharmaceutical (002038.SZ) announced that the company recently received a notice from senior executive Ms. Liang Shujie on the completion of the shareholding reduction plan, with a total reduction of 0.5 million shares, accounting for 0.0487% of the total share capital of the company.
